INTRODUCTION
The regulation of heart size during postnatal development is a fundamental process directly relevant to remodeling of the heart in response to congenital heart diseases. Postnatal change in the size of the mammalian heart through replication of cardiac muscle cells (cardiomyocytes [CMs] ) is thought to be limited by early postnatal terminal differentiation (Soonpaa et al., 1996; Walsh et al., 2010) . This notion was proposed as early as 1894 by Bizzozero, who suggested that replication of CMs ceases at birth and classified mature CMs as elementi perenni, or cells of static populations.
The view that CMs terminally differentiate in the neonatal period (by postnatal day 5 [P5]) is supported by evidence that during early preadolescence (from P5 to P14), the expression of genes responsible for cell-cycle reentry, mitosis, and cytokinesis falls precipitously (Walsh et al., 2010) . This change is preceded between P5 and P10 by extensive binucleation of CMs (Soonpaa et al., 1996; Walsh et al., 2010) , widely considered a marker of terminal differentiation; by P7, hearts lose regenerative capacity (Porrello et al., 2011) . Between P10 and P21 (weaning), estimates of S phase indicate that CMs are quiescent (Soonpaa et al., 1996) . Assessments of mitosis in murine CMs at select ages (Walsh et al., 2010) also support the conclusion that replication ceases by P5-P7.
In mammals, the heart grows markedly between the immediate postneonatal period and puberty. If CMs are terminally differentiated, this growth should be due almost entirely to an increase in the volume of constituent CMs, which throughout postneonatal life account for 80% of the volume of the myocardium . In humans, a disparity between changes in CM volume and heart volume is readily observed between birth and 20 years (Mollova et al., 2013) . This disparity suggests a 3.4-fold increase in the CM population number (CPN). Senyo et al. (2013) have investigated the source of such new CMs in the mouse, the only species in which the timing of terminal differentiation has been evaluated. They report that CMs are added to postneonatal hearts at a rate of 0.76% per year and that these new cells are derived from a small fraction (<0.2%) of mononuclear CMs that retain proliferative capacity. This rate of CM addition predicts only a negligible ($1.06-fold) increase in CPN between the onset of terminal differentiation (around P5) and puberty (P35).
Here, we show a 1.4-fold increase in CPN during the preadolescent period, which occurs as a discrete proliferative burst on P15 initiated by a surge in thyroid hormone (T3). Proliferation is evident from an increase in CPN, the re-expression of mitosisrelated genes, readily apparent mitotic figures in mature monoand binuclear CMs and, consistent with cell division giving rise to smaller progeny, a sharp fall in both mono-and binuclear CM volume. The brevity of this proliferative burst could explain why it has previously gone undetected. This study provides compelling evidence for retention of CM proliferative competence long after the neonatal period, which requires a significant revision of the generally accepted view of CM terminal differentiation.
RESULTS
Disparity between Heart and CM Growth during Postnatal Development Between early preadolescence ($P10) and puberty ($P35), mouse body weight nearly doubles each week ( Figure 1A ). Assuming that circulatory volume increases in direct proportion to body weight, circulatory volume should increase by $15% each day, with equivalent increases in heart weight (Figures 1B and 1C) . Echocardiography shows that between P10 and P35, Figure 1 . Rapid Body Growth Involves CM Elongation and Eccentric LV Remodeling (A and B) Concomitant increases in body and heart weights of wild-type (WT) mice during the period from preadolescence (P10) to just after puberty (P35). (C) Increase in heart size from P10 to P35 is illustrated by hematoxylin and eosin-stained coronal heart sections. (D-L) Hemodynamic and cardiac and CM morphological changes in WT mice from P10 to P35. LVEDD and LVED volume indicate left ventricular end-diastolic dimension and volume, respectively; LV FWd, LV free wall thickness in diastole. Data are shown as mean ± SEM. The number of animals, or cells, studied is shown by n. ***p < 0.001. stroke volume increases 3.5-fold (p < 0.001) ( Figure 1D ). This is associated with left ventricle (LV) chamber remodeling, giving an 86% increase in LV end-diastolic dimension (LVEDD) (p < 0.001; Figure 1E ) and a 4.6-fold increase in LV volume at diastole (p < 0.001; Figure 1F ), without a significant change in LV free wall thickness at diastole (FWd or h) ( Figure 1G ). This adaptation produces a 52% decrease in the LV h/R i ratio (where R i is the internal LV chamber radius; Figure 1H ), consistent with eccentric hypertrophy, and maintains the LV weight-to-stroke volume ratio (1.76:1 at P10 versus 1.78:1 at P35). Also between P10 and P35, the LVEDD length-to-diameter ratio decreases by 40% (p < Figure 2 . A Period of CM Proliferation during Preadolescent Heart Growth (A) Total numbers of cardiomyocytes in both cardiac ventricles of mice (CM population number [CPN] ). The number of animals studied is shown in square brackets. (B-G) Enhanced expression of the mitosis-related genes Ki67, Cyclin B1, polo-like kinase-1 (Plk 1), aurora A, Survivin, and anillin on P15. Also note suppressed expression of all these genes in P35 hearts (p < 0.001 versus P13 values). Values were determined using RNA prepared from five animals at each time point. (H-J) An example of flow cytometric analysis of BrdU + /cardiac troponin T + (cTnT + ) CM-derived nuclei obtained from a mouse given a single intraperitoneal injection of BrdU on the night of P14 and then sacrificed on P18. (K) A representative example of analysis of BrdU uptake (at P14 evening) and ploidy, indicating that 96.4% of nuclei were 2n and 3.6% were 4n (on P18) in this cell preparation from a single heart. Data are shown as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. 0.001; Figure 1I ), indicating increased LV sphericity. At the cellular level, CM length increases by 46 mm (p < 0.001; Figure 1K ) between P10 and P35, with minimal (+1 mm) change in diameter (p < 0.001; Figure 1L ).
The increase in ventricular weight between P10 and P35 (21.7 ± 1.43 mg, n = 9 at P10 versus 75.3 ± 5.56 mg, n = 5 at P35; +3.47-fold; p < 0.001) exceeds the increase in ventricular CM volume by 1.7-fold, calculated on the basis of a cylindrical model (18.2 ± 0.31 pl, n = 511 at P10 versus 36.3 ± 0.78 pl, n = 497; +1.99-fold; p < 0.001). This disparity between increases in heart and CM volume suggested an increase in CM numbers during preadolescence.
Extensive CM Proliferation in the Preadolescent Heart
We determined total CM numbers in ventricular myocardium by enzymatic disaggregation and direct cell counting. Estimates of total CM numbers (summarized in Figure 2A ) identify two distinct increases in CPN: an $40% increase between P1 and P4, and a further $40% increase ($500,000 CMs) between P14 and P18. A total of 22% of the post-P14 CPN increase occurred by $4:00 p.m. on P15 (P15 afternoon or P15A; p < 0.001; Figure 2A ), with no further change between P18 and P365. Because variable CM yields among mice of different ages might confound our count, we calculated the CM fraction of myocardial volume-to-CM volume ratio, a yield-independent method for estimating CM numbers (Chaudhry et al., 2004) , and found 1.26 ± 0.03 3 10 6 CMs in both ventricles at P14 (n = 10) versus 2.2 ± 0.06 3 10 6 at P18 (n = 5) (p < 0.001). Thus, both a hemocytometer-based method and a yield-independent method show a large increase in CM numbers between P14 and P18. The latter method, because it requires several assumptions, likely overestimates the increase. Collectively, these data indicate that the preadolescent increase in CPN results from a discrete CM proliferative burst at $P15, rather than continuous low-level CM addition.
To determine the time of onset of mitosis, we measured the expression of several mitosis-promoting genes in the cardiac ventricles daily from P13 to P16 (Figures 2B-2G ). We found $5-to 12-fold increases in mRNA levels (p < 0.05) of all these genes on the morning ($9:00 a.m.) of P15, with levels on P16 falling to near-P13 levels. Thus, CMs are in M phase as early as 9:00 a.m. on P15. Assuming that the combined duration of S and G 2 phases is $10 hr (for a 24 hr cell cycle), S phase could start around 10:00 p.m. on P14. To identify S phase timing, we gave a single intraperitoneal injection of bromodeoxyuridine (BrdU) (bloodstream half-life $2 hr; Kriss and Revesz, 1962) at $9:30 p.m. on the night of P14. Mice were sacrificed on P18 and CMs isolated and purified to remove non-CMs; their nuclei were then liberated by lysis and analyzed by flow cytometry (an example is shown in Figures 2H-2J ). More than 99% of nuclei from CM-enriched cardiac cells were cTnT positive, arguing against significant contamination by non-CM nuclei. Flow cytometry further indicated that 11.3% ± 1.9% (n = 6) of CMderived (cardiac troponin T [cTnT]-positive) nuclei were BrdU positive (e.g., Figure 2J ). BrdU's short half-life in the circulation makes it unlikely that all CMs entering S phase on the night of P14 would be labeled by a single intraperitoneal BrdU pulse, but cell/nuclear divisions during the 3-day chase period would increase the number of BrdU-labeled nuclei. Thus, while our findings do not establish the number of nuclei entering S phase on the night of P14, they do show that a new S phase in CMs begins late on P14.
The long chase period also determined that the BrdU-labeled nuclei underwent nuclear division after labeling on the evening of P14. By the end of the chase period, the majority of the BrdUlabeled CM nuclei were 2n (96.4% ± 0.48% were BrdU + 2n nuclei and 3.6% ± 0.5% were BrdU + 4n nuclei; n = 5/group) ( Figure 2K ). Moreover, despite this post-P14 DNA synthesis in CMs, ploidy was not increased between P14 and P18 ( Figure S1 available online). Together, these findings indicate efficient karyokinesis.
We next identified mitotic CMs by monitoring coexpression of aurora B and the sarcomeric marker protein a-cardiac muscle actin (SaA) by confocal microscopy. The subcellular localization of aurora B is dependent on cell-cycle phase, so it can be used to distinguish between potential outcomes of progression into M phase (Carmena and Earnshaw, 2003) . Transverse sections of ventricles of mice sacrificed between 8:00 a.m. and 12:00 p.m. revealed a 36-fold increase in LV CM mitoses between P14 and P15 (p < 0.001) followed by an abrupt 5.8-fold decrease between P15 and P16 (p < 0.001) ( Figures 3A-3E ). These changes paralleled changes in expression of mitosis-promoting genes ( Figures 2B-2G ). Nuclear localization of aurora B in most of the mitotic CMs indicated that these cells were in prophase ( Figure 3B ).
Mitotic CM nuclei were not uniformly distributed throughout the LV wall, being 2.6-fold more abundant in subendocardial than in subepicardial myofibers of the P15 LV (p < 0.01; Figures  3B and 3F ). In these transverse cross sections, CMs in the subendocardium are cut along their short axes, while CMs in the subepicardium are cut along their long axes; these latter myofibers are oriented circumferentially in the LV wall ( Figure 3B ).
We also found that 14.5% ± 2.6% of LV CM nuclei were in mitosis versus 0.73% ± 0.4% in the right ventricle (RV) ( Figure 3E ) (n = 5/group; p < 0.001). Figures S2A-S2C illustrate this differential distribution of mitotic CMs in a transverse section of P15 heart, which is in contrast to the broad distribution of mitotic CMs in P2 neonatal heart ( Figures S3A-S3C) .
To verify the abundance of mitotic CMs in P15 cardiac ventricles, we purified CMs after enzymatic disaggregation, and used a-sarcomeric myosin heavy chain (a-MHC) and aurora B immunofluorescence to identify CMs in M phase. Approximately 10% of total mitotic P15 CMs were mononuclear (had an aurora B-positive nucleus or aurora B localized at the anaphase spindle midzone), and $90% were binuclear (aurora B-positive nuclei or aurora B localized at the anaphase spindle midzone of 2 pairs of nuclei) ( Figure 3G ). A total of 34.2% ± 4.4% and 30.8% ± 2.7% of mono-and binuclear CMs, respectively, were in M phase (n = 6) ( Figure 3H ); this is $2-fold higher than in immunohistochemical analyses ( Figure 3E ), which have been shown to underestimate mitoses (Mollova et al., 2013) .
In some mitotic binuclear CMs, we found sarcomeric structures on the periphery (e.g., Figure 3G shows a binucleate CM in anaphase, labeled ''A''). Localized disruption of sarcomeres may facilitate chromosome movement and cytokinesis but could also adversely affect LV function. However, cardiac contractility was similar in P14 and P15 hearts (LV fractional shortening: 35.8% ± 3% in P14 hearts versus 35.1% ± 2.3% in P15A hearts; n = 6/group; p = 0.87), suggesting that the sarcomeric disruption noted in P15 CMs was not sufficient to depress LV function.
Cytokinesis requires the formation and constriction of a mature contractile ring. Aurora B and the central spindlin component mitotic kinesin-like protein (MKLP1) make independent contributions to this process (Lewellyn et al., 2011) . Because most of the mitotic CMs in P15A hearts were in the LV subendocardium (where myofibers are oriented longitudinally), we examined CM MKLP1 localization in longitudinal sections, where axial views of CMs in late mitosis are more likely. Approximately 4% of CMs contained MKLP1 between pairs of CM nuclei (Figures 3I and 3J) . The frequency of these CM MKLP1 + events and of mitotic figures ( Figures S4A-S4E ) supports CM proliferation in P15 hearts.
Modes of Mitosis in Mononuclear and Binuclear CMs
Mononuclear CMs that have entered M phase can produce two mononuclear daughter cells via a conventional cell cycle. We calculated the number of mono-, bi-, and multinuclear CMs added to the ventricles between the morning of P14 (9:00 a.m.) and the afternoon of P15 (4:00 p.m.) by multiplying the average CPN ( Figure 2A ) by the percentages of CMs that were mononucleate, binucleate, or multinucleate at these times (Figures 4A-4D; Table S1 ). The most striking change was the addition of 11.5 3 10 4 mononuclear CMs (2.3-fold increase). For extant mononuclear CMs to be the sole source of this addition, all mononuclear CMs present at P14 (calculated to be $8.5 3 10 4 cells) would need to undergo mitosis on P15. However, the rate of mitosis in mononuclear CMs on P15 was only $34% (Figure 3H) ; this could account for at most 2.9 3 10 4 cells (or 25% of the addition). Moreover, mitosis of mononuclear CMs does not explain the origin of the 6 3 10 4 binuclear, and the 9.4 3 10 4 multinuclear, CMs added between P14 and P15A (Table S1 ). Binuclear CMs are thought to be incapable of division, because polyploidy is considered to indicate terminal differentiation. However, Miyaoka et al. (2012) propose that binuclear hepatocytes that have entered M phase assemble all condensed chromosomes from two nuclei and produce two mononuclear daughter cells, so that a binuclear cell is ''consumed'' with the birth of two mononuclear cells. Our calculations do not support this as the dominant mechanism, because binuclear CM numbers increase by $6% (or 6 3 10 4 cells). Nonetheless, the finding that $90% of all P15 mitotic CMs are binucleate (Figure 3G ) suggests a major role for polyploid cells in the CM hyperplastic burst. The initiation of M phase and karyokinesis at each nucleus of a binuclear CM, followed by cytokinesis between pairs of newly generated daughter nuclei, could yield two small mononuclear cells at the poles, with a binuclear cell remaining at the center. The two nuclear divisions would each contribute one nucleus to the binuclear daughter cell. We refer to this as the ''2+1 cell cycle.'' In vitro examples of a 2+1 cell cycle in a binuclear CM have been observed (Engel et al., 2005) . Alternatively, mitotic binuclear CMs could undergo acytokinetic mitoses Figure 2A ). We calculated the number of mono-, bi-, and multinuclear CMs that are added to the cardiac ventricles by multiplying the average CPN (Figure 2A ) with the percentage of CMs that were mono-, bi-, or multinuclear at these developmental ages (shown in Figures 4A-4C ). In (A)-(D), the number of animals studied is shown by the value in square brackets.
(E-H) Volume (E and F), width (G), and length (H) of mono-and binuclear CMs in P14, P15A, and P18 mouse hearts. The volume of individual CMs is represented by a red (mono-CM) or green (bi-CM) dot and was from the hearts of five mice at each time indicated (E and F). In (G) and (H), histograms represent average widths or length of CMs (n = 69-107 mono-CMs/group and n = 391-512 bi-CMs/ group) from five mice at each time indicated.
(I) Scheme illustrating potential modes of cell cycling during maturational heart growth. Mononuclear CMs undergo a conventional cell cycle to replicate. Binuclear CMs remain static or undergo cell division. This involves each of the two nuclei undergoing karyokinesis, with cytokinesis taking place between nuclei pairs. This generates two mononuclear CMs at the two poles and a smaller binuclear CM remains at the center. Overall, these processes increase the number of mononuclear CMs, without greatly changing the number of binuclear CMs. However, between P14 and the afternoon of P15 (P15A), mono-and binuclear CM volume decreases because smaller daughter cells are generated from larger preexisting CMs. Data are shown as mean ± SEM. **p < 0.01; ***p < 0.001. See also Figure S1 and Table S1 .
to yield multinuclear CMs or not proceed beyond prophase (i.e., abortive mitosis). We considered these possibilities because confocal immunocytochemical studies with aurora B revealed many binuclear CMs in prophase; others displayed dual karyokinesis with evidence of a spindle midzone between the nuclei in each pair (that is, postkaryokinesis) (e.g., Figure 3G , inset). If a significant number of 2+1 cell cycles occur, then the volume of binuclear cells should decrease precipitously between P14 and the afternoon of P15. Consistent with this scenario, the average volumes of bi-and mononuclear CMs decreased by 60% (p < 0.001) and 43% (p < 0.001) ( Figures 4E-4H) , respectively, despite an $10% increase in heart weight (from 35.6 ± 0.86 mg, n = 10 at P14 to 39.1 ± 1.3 mg at P15, n = 11; p < 0.05). If all mitotic mononuclear CMs at P15 undergo a conventional cell cycle to yield two mononuclear daughter cells, we calculate that it would require only $7.3% of the binuclear CMs to undergo an unconventional 2+1 cell cycle in order to achieve the observed increase in total mononuclear CM numbers, including the 6 3 10 4 binuclear CMs that are added (presumably through subsequent endocycles in some mononuclear cells) between P14 and P15A. These concepts are schematically illustrated in Figure 4I . While some of the 9.4 3 10 4 multinuclear CMs added between P14 and P15 might be intermediates of the 2+1 cell cycle, most are unlikely to divide further because their numbers decrease by only $7% in the following 3 days ( Figure 4D ). The finding that binuclear CM size (but not numbers) decreases sharply (by $60%), as mononuclear CM numbers increase by 2.3-fold between P14 and P15, supports polyploid CM mitoses followed by cell division as the major component of the CM proliferative burst. and 69 ± 29 (n = 5) c-kit + /Nkx-2.5 + CM progenitors. These numbers are insufficient to account for the addition of $500,000 CMs between P14 and P18.
Thyroid Hormone Triggers Cardiac Growth and Hyperplasia during Early Preadolescence Despite a highly significant correlation (r 2 = 0.93; p < 0.0001) between heart and body weight between P2 and P84 ( Figure S5 ), from P11 to P18 heart weight increased more than body weight ( Figure S5 ). This suggests that the preadolescent increase in heart growth cannot be accounted for by rapid circulatory volume expansion (or body weight) alone. Immediately after P10, the rate of heart growth exceeded that of body growth ( Figure 5A ), resulting in a rapid 30% increase in heart-to-body weight ratio between P10 and P17 (p < 0.001). The initial phase of this increase, between P10 and P14, was by eccentric hypertrophy. This involved not only a 1.56-fold increase in cardiac mass (p < 0.001; Figure 1B ) but also increases in LV chamber dimensions (1.24-fold increase in LVEDD; p < 0.001) and volume (2.8-fold increase; p < 0.001) (Table S2) , with more prominent increases in CM length than width ( Figures  S6A-S6C ) but without CM hyperplasia (Figure 2A) . These changes caused a 22% decrease in the h/Ri ratio (p < 0.05; Table  S2 ), indicating an increase in LV wall stress based on the law of LaPlace. But ventricular a/b-MHC mRNA ratio also increased $5-fold (p < 0.01; Figure 5B ) and a-MHC levels increased 2.5-fold (p < 0.05; Figure 5C ), while atrial natriuretic factor mRNA levels (a marker of pathological hypertrophy) were not significantly increased ( Figure 5D ). This molecular and morphological signature suggests a 3,3 0 ,5-triiodo-L-thyronine (T3 or thyroid hormone)-mediated effect, since neither physiological nor pathological cardiac hypertrophy causes large increases in the a/b-MHC mRNA ratio (e.g., Perrino et al., 2006) , but T3 excess does (Haddad et al., 2008) . Consistent with this hypothesis, serum T3 levels increase 5.6-fold between P10 and P12 ( Figure 5E ). To determine if T3 is necessary for the post-P10 cardiac growth, we inhibited T3 biosynthesis with propylthiouracil (PTU). PTU administration from P7 decreased serum T3 levels at P14 by 43% (p < 0.05) (Figure 5E ), prevented the increase in the a/b-MHC mRNA ratio ( Figure 5B ), and reduced heart weight more than body weight, so that by P14-P18, the heart-to-body weight ratios of PTU-treated mice were not significantly different from P10 mice ( Figure 5F ). This is consistent with a high level of circulating T3 regulating cardiac growth during early preadolescence. The subsequent decrease in heart-to-body weight ratio between P16 and P21 ( Figure 5A ) was due to a reduced rate of heart growth (relative to the previous 5 days) ( Figure 1B) , during which body weight continued to rise ( Figure 1A ), but not due to a reduction in serum T3, which remained high between P12 and puberty ( Figure 5E ).
Hence, preadolescent growth is characterized by a bidirectional disparity in heart and body weight changes-first, between P10 and P16, when heart growth exceeds that of the body, and subsequently between P16 and P21, when body growth exceeds that of the heart. Together, these findings suggest that between P10 and P14, T3 critically modulates the mode by which body weight/circulatory volume drives heart growth, allowing a more rapid increase in heart size during early preadolescence.
We next evaluated the role of T3 in CM hyperplasia. Blockade of T3 biosynthesis abrogated the developmental increase in the CPN by P18 ( Figure 5G ). Also, a 7-day exposure of cultured P14 CMs to T3 (70 nM) produced an $2-fold increase in DNA synthesis (BrdU incorporation) (p < 0.05; Figure 5H ).
We then explored a potential link between T3 and insulin-like growth factor-1 (IGF-1) in preadolescent hearts. The IGF-1-R/ Akt pathway in the heart is both prosurvival and proproliferative (Dai and Kloner, 2011) ; IGF-1 is mainly secreted by cardiac fibroblasts (Horio et al., 2005) . Akt is required for physiological growth in response to IGF-1 stimulation (DeBosch et al., 2006) . T3 regulates IGF-1 mRNA in osteoblasts via an Igf1 thyroid hormone response element (TRE) (Xing et al., 2012) . IGF-1 causes fetal heart CM proliferation by activating the IGF-1-R/PI3K/Akt pathway (Sundgren et al., 2003) , and postnatal CM numbers are increased in transgenic mice with cardiac-restricted IGF-1 overexpression (Reiss et al., 1996) . We found that IGF-1 mRNA and IGF-1 expression are increased 2.3-fold (p < 0.05; Figure 6A ) and 39-fold (p < 0.05; Figures  6B-6F) , respectively, in P15 relative to P10 hearts. Activation of IGF-1-R requires phosphorylation that activates phosphatidylinositol-3 kinase (PI3K), which phosphorylates and activates Akt. PTU suppressed both phospho-Tyr 1161 -IGF-1-R/glyceraldehyde 3-phosphate dehydrogenase (GAPDH) ( Figure 6G and 6H) and phospho-Ser 473 -Akt/total Akt levels ( Figure 6I ), indicating the involvement of T3 in activating the IGF-1-R/Akt pathway in P15 ventricles.
Akt phosphorylates multiple substrates implicated in cell survival and heart growth. In CMs, nuclear localization of Akt is functionally important. Expression of constitutively activated Akt results in CM hypertrophy (Condorelli et al., 2002) , but nuclear overexpression increases CM numbers (Rota et al., 2005) . Akt was mostly localized to CM nuclei in P15 hearts (Figures 6J-6N) ; in P10 hearts, its localization was cytoplasmic. Consistent with the distribution of mitotic CMs ( Figures 3E and  3F ), Akt + CM nuclei were predominantly in the subendocardium of the P15 LV wall ( Figure 6N ) and were not detected in the RV. (F and G) Increase in heart-to-body weight ratio from P10 to P14, P15, and P18, and inhibition of these increases by PTU (F). PTU also prevents the increase in CPN between P10 and P18 (G).
(H) Treatment of cultured cardiomyocytes isolated from P14 mice with T3 for 7 days increased the percentage of BrdU + CMs (cTnT + ).
Data shown are the means ± SEM. The number of individual animals studied is shown by n. *p < 0.05; **p < 0.01; ***p < 0.001. See Figures S5, S6 , and S7 and Table S2 .
Collectively, these findings support a role for T3 in triggering the P15 CM hyperplastic burst.
Cardiac Function after Myocardial Infarction in Neonatal and Early Postnatal Hearts
Extensive cardiac regeneration after injury, leading to restoration of the ventricular wall without scar formation, is observed in P1, but not P7 or P14, mice (Porrello et al., 2011 (Porrello et al., , 2013 . This is consistent with the prevailing view that CMs permanently exit the cell cycle by the end of the neonatal period (at $P5). However, prominent CM proliferation at P15, as shown above, might allow cardiac regeneration. We thus evaluated the early regenerative potential of P15 mouse hearts by subjecting them to myocardial infarction and comparing their response to those of P2 and P21 animals. Figure 7A shows examples of P2-and P15-injured hearts at 7 or 21 days postinfarction (dpi). Despite no significant differences in infarct sizes at 1 dpi ( Figure 7B ), P21 infarct sizes were 6.8-fold greater (p < 0.001) at 7 dpi than P2 infarct sizes, while infarct size was intermediate in P15 hearts; infarct size was also 2.4-fold greater (p < 0.01) at 7 dpi in P21 versus P15 hearts ( Figure 7B ). We next compared levels of DNA synthesis in CMs within the remote (nonischemic) and border zones, as compared to control regions in age-matched sham-operated mice. We gave BrdU intraperitoneally at 1 and 3 dpi and determined the number of BrdU + CMs in LV myocardium at 7 dpi by immunohistochemistry and confocal microscopy. There was robust cell-cycle activity throughout the LV myocardium in both sham-operated and infarcted P2 hearts but $10-fold lower levels of cell-cycle activity in the border zone of P15 mice (versus that in injured P2 hearts; p < 0.05) ( Figure 7C ). BrdU + CMs were virtually undetectable in the border zone of infarcted P21 hearts ( Figure 7B ). The detrimental impact of infarction on LV function (LV fractional shortening and ejection fraction; Figures 7D and 7E , respectively) and LV wall thinning ( Figure 7F ) was not evident in P2 hearts at 7 dpi, as may be expected with extensive regenerative repair ( Figures 7A and 6C) ; it was intermediate at P15 and severe at P21 ( Figures 7D and 7E ). These differences in functional and morphological outcomes at 7 dpi in P2 and P15 mice were independent of the size of the initial infarct ( Figure 7B ). Thus, in murine hearts, the capacity for cardiac regeneration after P15 is intermediate between that at P2 and at P21.
DISCUSSION
Although CM terminal differentiation has been extensively studied, when it occurs and what role it plays in early postnatal heart maturation are fundamental questions that remain largely unanswered. Here, we show that over a precisely timed interval during the third week of life, $500,000 CMs are added to the preadolescent mouse heart. This represents an $40% increase in CPN, with CM numbers remaining static thereafter. These new cells are derived from CMs previously believed to have lost, shortly after birth, their capacity to divide. Further, we find evidence that thyroid hormone triggers the hyperplastic burst at P15. Hence, it is likely that terminal differentiation in CMs does not occur before P15: these findings question the 100-year-old concept that CMs terminally differentiate in the neonatal period (Bizzozero, 1894) .
The Timing of CM Terminal Differentiation in Postnatal Murine Hearts
Terminal differentiation in mature mammalian CMs means that these cells have permanently withdrawn from the cell cycle. Mechanisms responsible might include a marked suppression of basal levels of expression of cell-cycle genes that promote cell division and/or increased expression of genes that inhibit the cell cycle (Poolman and Brooks, 1998) . When CMs are forced to reenter the cell cycle, as with forced overexpression of S phase cyclins, endoreplicative cell cycles (or endocycles) produce large polyploid cells (Soonpaa et al., 1997) . Alternatively, cells that proceed past the G 2 /M phase checkpoint undergo acytokinetic mitoses to generate large multinucleate cells (Soonpaa et al., 1997) . However, despite prominent cell-cycle checkpoints that produce this phenotype, a small number of preexisting CMs in adult hearts can undergo cell division, which over time may replace cells lost by apoptosis (Senyo et al., 2013) . These may be a small subset of CMs that have retained replicative competency, or they may reflect a stochastic equilibrium between replicative competence and terminal differentiation that heavily favors the latter. This has been taken to suggest that, as murine CMs exit the neonatal period (immediately after P5), most undergo an endocycle that produces binuclear cells, which are considered a defining manifestation of terminal differentiation (e.g., Walsh et al., 2010) . Here, we show that numerous CMs reenter the cell cycle on the night of P14; this culminates in cell division during P15. Several lines of evidence suggest that new CMs are derived from preexisting CMs. First, aurora B labeling indicates that $30% of both mono-and binuclear CMs are in mitosis on the morning of P15, and MKLP1 expression in $4% of LV subendocardial CMs indicates impending cytokinesis. MKLP1 plays an essential role in midbody formation and completion of cytokinesis (Zhu et al., 2005) and marks imminent cytokinesis. Second, cell counting indicates that 2.6 3 10 5 CMs are added to the cardiac ventricles between P14 and P15A. Third, consistent with cell division giving rise to small progeny, the average mono-and binuclear CM volume abruptly decreases by $40%-60% and, consistent with extensive cytokinesis, this is associated with a loss of large mono-and binuclear CMs observed in P14 ventricles. Fourth, addition of $500,000 CMs to the cardiac ventricles between P14 and P18 occurs with minor changes in polyploidy or acytokinetic mitosis (as assayed by multinucleation). On the morning of P15, $90% of mitotic CMs (A) Representative coronal sections of hearts from P2 and P15 mice at 7 and 21 days postmyocardial infarction (MI; dpi) induced by left anterior descending coronary artery ligation. Sections are stained with picrosirius red to delineate scar tissue (arrows) and fast green to delineate viable myocardium. Note the virtual absence of scar tissue in P2 MI mice at 7 and 21 dpi compared to mice whose MI occurred at P15. (B) Percent infarct size relative to the LV of P2, P15, and P21 mice 1 and 7 dpi determined from 2,3,5-triphenyltetrazolium chloride and picrosirius red with fast green-stained sections, respectively. Note the differences in infarct sizes at 7 dpi despite similar infarct sizes at 1 dpi. (C) BrdU + /a-MHC + CMs in the remote (nonischemic) and border zones of P2, P15, and P21 hearts at 7 dpi, showing fewer cells with evidence of DNA synthesis (BrdU incorporation) in P15 hearts compared to P2 hearts and the absence of such cells in P21 hearts.
(D) LV fractional shortening (FS) of P2, P15, and P21 hearts at 7 dpi or sham operation, determined from B-mode echocardiographic views at the midpapillary or apical (peri-infarct) levels. Note the reduction in FS in P15 hearts and the more marked reduction in FS in P21 hearts.
(E) Echocardiographically determined LV ejection fraction (EF) of P2, P15, and P21 hearts at 7 dpi or sham operation. Consistent with the changes in FS, note the significant reduction in EF in the P21 hearts.
(F) Echocardiographically determined LV wall thickness of P2, P15, and P21 hearts at 7 dpi, expressed as a ratio of wall thickness in the periinfarct or control regions to that at the midpapillary level. Consistent with the reductions in FS and EF, note the significant reduction in LV wall thickness in the P21 hearts. Data shown are the means ± SEM. In all studies, n = 3-7 animals for each individual evaluation. *p < 0.05; **p < 0.01; ***p < 0.001; n.s., nonsignificant.
are binucleate and, based on nuclear localization of aurora B, most appear to be in prophase. Those that are in anaphase display localized disruption of sarcomeres around their nuclei but no loss of contractile function (LV fractional shortening) during the CM replicative burst. Finally, there is a prominent 1-day increase in many mitosis-regulating genes in P15 heart. These considerations indicate that murine CMs are not terminally differentiated during early preadolescence and challenge the notion that binuclear CMs cannot divide. We suppose that the synchronized and temporally restricted nature of the CM proliferative burst in P15 hearts has inhibited its detection. Soonpaa et al. (1996) found near-negligible levels of S phase in P10-P21 CMs using a 2 hr in vivo 3 H-thymidine labeling protocol. This approach could miss a short synchronized proliferative burst in which S phase starts during the night of P14 and ends before the morning of P15 (S phase duration in CMs is not known, but it could last $4 hr in a 24 hr cell cycle). In support of this notion, we found extensive nuclear localization of aurora B, indicating that these CMs have just passed the G 2 /M phase transit point by the morning of P15. Walsh et al. (2010) studied CM mitosis in P14, but not P15, CMs. Relative to P15 hearts, we observed very low levels of CM mitoses in P14 or P16 hearts. Porrello et al. (2011) report that hearts retain significant cardiac regenerative potential for a brief time after birth. The link between regenerative potential and postnatal cell-cycle arrest, as assessed by CM binucleation, was suggested to indicate a brief neonatal ''cardiac regenerative window'' that closes before P7. We show here that CMs are not terminally differentiated at P15. To ask if regenerative repair is possible at P15, we assessed recovery from myocardial infarction in neonatal and postnatal hearts (P2, P15, and P21). Our findings indicate an intermediate phenotype in hearts injured at P15 (ejection fraction unchanged but with a 64% depression of fractional shortening at the periinfarct level) relative to those injured at P2, which showed a high degree of repair after injury (ejection fraction unchanged with no depression of fractional shortening at the peri-infarct level). Hearts injured at P21 (ejection fraction reduced by 40%, with $90% depression of fractional shortening at the peri-infarct level) showed no evidence of injury-induced CM cell-cycle reentry. This intermediate cardiac pathology in P15-injured hearts might be due to the level of CM proliferation: BrdU incorporation into CMs in the border zone was lower than that in P2-injured hearts, possibly because CMs terminally differentiate within the 7 dpi follow-up period. Upregulation of the T3-triggered IGF-1/IGF-1 receptor (IGF-1R)/phospho-Akt axis at P15, which is prosurvival (Dai and Kloner, 2011) , may also have played a role in attenuating cardiac pathology in P15-versus P21-injured hearts. Finally, immune responses to injury influence cardiac regeneration and functional outcomes (Xin et al., 2013) , factors that change profoundly as the neonate transitions into preadolescence (Levy, 2007) . These complexities would need elucidation to enable efficient regenerative repair in preadolescent hearts.
Preadolescent Heart Growth Occurs via a Distinct Form of Physiological Hypertrophy
It is axiomatic that the main purpose of heart growth during preadolescence is to increase stroke volume and cardiac output to accommodate a growth spurt that almost quadruples body weight (and hence circulatory volume) of P10 mice in just 25 days. Our studies indicate that maturational heart growth, while sharing similarities with other forms of cardiac hypertrophy, shows differences that suggest that it is a distinct form of physiological hypertrophy.
Mechanistically, LV volume overload of mitral regurgitation leads to fiber elongation, chamber enlargement, and eccentric hypertrophy (Grossman et al., 1975) . Moreover, an increase in LV sphericity and a decrease in h/Ri ratio cause an increase in LV end-diastolic wall stress. By contrast, increases in LV chamber volume during endurance exercise are accommodated by elliptical remodeling of the heart (Schiros et al., 2013) . This limits the increase in LVEDD and, hence, based on LaPlace's law (T = P 3 R i /h, where T is the tension or wall stress and P is the pressure difference across the LV wall), wall stress and myocardial oxygen demand do not need to increase as much as with an equivalent increase in LV volume due to spherical remodeling. We find that LV chamber sphericity increases, and the h/R i ratio decreases (by $50%), during maturational heart growth. Thus, LV wall stress must increase progressively during maturational growth. Despite this, stroke volume increases, most likely due to an increase in a-MHC expression and to CM proliferation. Maturational heart growth thus combines CM proliferation with an increase in a-MHC, which correlates directly with overall cardiac performance (Krenz and Robbins, 2004) , thus indicating a distinct form of cardiac remodeling.
Hyperplastic Heart Growth of Preadolescence Involves Hemodynamic-Endocrine Interplay
We observed that preadolescent CM hyperplasia was abrogated by inhibition of T3 biosynthesis. Moreover, T3 promoted cellcycle reentry of cultured P14 CMs. While these findings are consistent with T3 being both necessary and sufficient for the preadolescent proliferative burst, the fact that the spike in T3 occurs well before proliferation begins, as well as the uneven but nonrandom distribution of mitotic CMs within the LV wall, suggests a greater level of complexity. T3 also causes CMs to elongate (Pantos et al., 2007) , which is expected to increase LVEDD and hence wall stress. We showed that LVEDD increased markedly between P10 and P14. During isovolumic LV contraction, wall stress is higher in subendocardial than in subepicardial regions (Mirsky, 1973) . And, as shown in fetal (Saiki et al., 1997) and early neonatal CMs (Sedmera et al., 2003) , wall stress stimulates CM replication. Thus, we speculate that the preadolescent CM proliferative burst involves an orchestrated interplay between a permissive increase in T3 level and a regional increase in wall stress ( Figure S7 ).
These unique features of maturational heart growth are likely to be important for maintaining cardiac performance during a critical period of body growth, which is unsupported by maternal/placental nutrient and oxygen supply and involves increasing circulatory pressures. Furthermore, the finding that CM proliferative capacity is sustained well beyond the neonatal period may have important clinical implications. For example, congenital hypoplastic heart syndromes are often treated with palliative surgery and eventually cardiac transplantation. If human CMs, like those of the mouse, continue to divide efficiently during preadolescence, this may provide a basis for stimulating cardiomyogenesis in young patients by the administration of T3. Indeed, a therapeutic benefit of T3 in the postoperative period has been reported in newborn children undergoing operations for complex congenital heart diseases (Chowdhury et al., 2001 ).
EXPERIMENTAL PROCEDURES Animals
To minimize size variation, only male mice (C57BL/6J) from litters of six to seven were used, unless otherwise indicated. To avoid potential inaccuracies in the timing of birth, only animals with confirmed birthdates were used. Animals were handled according to Emory University or Victor Chang Cardiac Research Institute institutional animal care and use committee guidelines.
Echocardiography
Echocardiography was performed under 2% isoflurane anesthesia as described previously (Li et al., 2008 ) (see Extended Experimental Procedures).
Ventricular Myocardial Wall Volume
Ventricular volumes were determined from ventricular weights and the known specific gravity of muscle. See Extended Experimental Procedures for details.
Myocardial Infarction and Infarct Size Determination
Mice were anesthetized and subjected to left anterior descending artery ligation via left thoracotomy. Infarct sizes were determined on triphenyl tetrazolium chloride (1 dpi) or picrosirius red/fast green-stained (7 dpi) sections, using Image J software (NIH) or scanning by Power Mosaic microscopy, respectively (see Extended Experimental Procedures).
CM Isolation, Nucleation, Ploidy, and Dimension Analyses CMs were isolated by Langendorff perfusion and distinguished from non-CMs by cytoplasmic size and phase-contrast microscopy. Samples (20 ml; $150 CMs/aliquot) were loaded in the counting chamber with a wide-bore pipette and counted in triplicate using a hemocytometer. After purification, CMs were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI) for nucleation counts, which were plotted as percentage of counted CMs using procedures described by us previously (Li et al., 2008) . CM dimensions were measured using NIS-Elements 3.0 software (Nikon) (see Extended Experimental Procedures).
Immunofluorescence
CMs and hearts were fixed and subjected to immunocytochemical and immunohistochemical evaluation, respectively, as described previously (Li et al., 2008 ) (see Extended Experimental Procedures).
Quantitative RT-PCR and Western Blot Analyses RNA prepared from snap frozen heart ventricles was subject to quantitative RT-PCR using standard techniques (see Extended Experimental Procedures for details). Proteins extracted from snap frozen hearts were fractionated by SDS-PAGE and subjected to immunoblotting, as described elsewhere (Li et al., 2008 ) (see Extended Experimental Procedures).
CM Culture and Cardiac Stem Cell Analyses
CMs isolated from P14 hearts were cultured and subjected to T3 and BrdU treatment and cardiac stem cells determined by flow cytometer analysis after staining for c-kit and Nkx2-5 as detailed in Extended Experimental Procedures.
Serum T3 Measurement
Serum T3 levels were determined with a T3 ELISA kit (Alpha Diagnostic International).
Statistics
Data are presented as the mean ± SEM. 
